FDA Breakthrough Prapela has received FDA Breakthrough Device Designation, signaling strong validation of its noninvasive neonatal stimulation therapy. This creates a credibility anchor for engaging hospital procurement, NICUs, and pediatric care networks seeking innovative, approved devices.

Clinical Focus Funding and awards totaling over $8M support clinical evaluation for opioid-exposed newborns and apnea of prematurity. This highlights a prioritized patient population and a pathway for expanding sales within neonatal care, neonatal abstinence syndrome programs, and perinatal networks.

Target Market Operating in medical equipment for newborn respiratory support with a small team, Prapela presents opportunities to partner with larger pediatric device distributors and hospital systems seeking scalable, noninvasive respiratory solutions for preterm and at-risk infants.

Recent Innovations Product launches such as the Prapela SVS baby box demonstrate expansion into newborn comfort and safe sleep environments, suggesting cross-sell potential with neonatal care bundles, sleep safety programs, and family-centered care initiatives.

Technical & Partnerships Tech stack involvement with cloud, analytics, and e commerce platforms indicates potential for data-driven outcomes proofs, remote monitoring capabilities, and streamlined direct-to-hospital or channel partner sales, augmented by existing CRM and marketing tooling.